NEW YORK--(BUSINESS WIRE)--The acquisition of Kythera Biotherapeutics, Inc. (Kythera; NASDAQ: KYTH) by Allergan plc (Allergan; NYSE: AGN; f.k.a. Actavis plc) for approximately $2 billion is in line with expectations, according to Fitch Ratings. Fitch has reviewed the transaction but is taking no ratings actions. NOTE: Actavis plc changed its legal name and stock ticker to Allergan plc and AGN, respectively, effective June 15, 2015. Though ratings flexibility is still limited for Allergan, Fitch